Welcome to GLG Pharma

Our Technologies for Cancer are Unique.

Get started with us to learn how.

Great Drug Discovery is Reliant on Reproducible, Relevant, and Actionable Results from the Lab.

Isolating the Wrong Cancer Cell Clonal Populations Leads to Clinical Drug Failure

Tumor and Patient Heterogeneity and not being able to isolate and identify all the cancer players; Drivers, Passengers, Sleepers, Enablers, and Ambassadors means your drugs and drug combinations will not survive the clinical trials process, no matter how much you and the team know about the mechanisms of action, binding, distribution, efficacy, and safety. Heterogeneity will win.

What We Do Sets Us Apart

Screenshot 2021-12-02 090421
Designing Media for the Cancer

Leverage the 20+ years of cancer cell culturing knowledge imbedded in our cancer cell culturing media. Saves you time and will rescue your research and your business. Promise.

CCS System
Available Media for Cancer Cells

Leverage the awesome cancer cell culturing media that saves you time and will rescue your discovery research. Promise.

growing_plant
Partnering

Leverage the combination of cancer cell technologies and drug discovery for your research projects. Partnering doesn't have to be difficult and it can save money. Promise.

An Example of Our Media for Cancer Cell Culturing

Epithelial ExampleOvarian Tumor Cells

In xenographs, morphology is also better preserved

Screenshot 2022-10-24 150106

 

 

 

Cancer Cells Image

Our Approach Works

Let our tested and proven approach to culturing cancer cells help you and your team identify the best technologies, diagnostics, and drug candidates whether small molecule or large biomolecules, using the right media for the right cancer cells is the key.

96%

Match to Patient's RNA/DNA tumor profiles in lab cancer cultures

300%

Increase increase in the ability to culture ovarian cancer cells in the lab using the GLG Pharma INCE medias

Let's Build Something Together.

Partnering Interest